Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus OLOPATADINE HYDROCHLORIDE.
ACTAHIST vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
1.34 mg (one capsule) orally twice daily.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer